Previous 10 | Next 10 |
home / stock / awkn:cc / awkn:cc news
Awakn has raised approx. CAD$775K to grow its Nordic clinics business Toronto, Ontario--(Newsfile Corp. - October 25, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (" Awakn "), a revenue-generating biotechnology company researching, developing, and commercializing th...
Awakn delivered revenue growth of 34% in Q2 Awakn also announces closing of first tranche of private placement financing Toronto, Ontario--(Newsfile Corp. - September 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researchi...
Toronto, Ontario--(Newsfile Corp. - September 12, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Dis...
Agreement Provides 12-Month Exclusive Period to Agree in-Licensing Deal for Proprietary Formulation of Ketamine Toronto, Ontario--(Newsfile Corp. - August 25, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company research...
Licensing Partnership with Wellbeings(R) marks entry into Canadian addiction treatment and relapse prevention market Toronto, Ontario--(Newsfile Corp. - August 18, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company res...
Awakn enters the U.S. addiction treatment and relapse prevention market Toronto, Ontario--(Newsfile Corp. - August 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing the...
REVITALIST LIFESTYLE AND WELLNESS LTD. (“Revitalist” or the “Company”) (CSE: CALM) (OTCQB: RVLWF) (FSE: 4DO) announces it has signed a licensing partnership agreement with Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (‘Awakn’)...
Phase III Trial to Cost approximately CA$3.75 million with Awakn's contribution expected to be approximately CA$1.25 million, Marks First Psychedelic Phase III Trial Ever to Receive Government Funding Toronto, Ontario--(Newsfile Corp. - July 20, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (...
Toronto, Ontario--(Newsfile Corp. - July 15, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a revenue-generating biotechnology company researching, developing, and commercializing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder...
Awakn Provides Business Update on Progressing its Lead Program from Phase II b to Phase III Toronto, Ontario--(Newsfile Corp. - July 5, 2022) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954), a revenue-generating biotechnology company researching, developing and commercializi...
News, Short Squeeze, Breakout and More Instantly...
AWAKN LIFE SCIENCES CORP. Company Name:
AWKN:CC Stock Symbol:
AQNC Market:
AWAKN LIFE SCIENCES CORP. Website:
Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Diso...
Toronto, Ontario--(Newsfile Corp. - Le 31 mai/May 2024) - Effective immediately, Awakn Life Sciences Corp. will be reinstated for trading. The Company has rectified the situation that gave rise to the suspension. _________________________________ Avec effet immédiat, Awakn Life Sc...
Toronto, Ontario--(Newsfile Corp. - Le 8 mai/Mai 2024) - Effective immediately, the following companies are suspended pursuant to CSE Policy 3. The suspensions are considered Regulatory Halts as defined in National Instrument 23-101 Trading Rules. Cease Trade Orders have been issued by one or mor...